Vaccine hesitancy: How to lift the brake?

被引:3
作者
Gaillat, J. [1 ]
机构
[1] Ctr Hosp Annecy Genevois, Serv Malad Infect CHANGE, Ctr Rech Clin, 1 Ave Hop, F-74374 Pringy, France
关键词
Vaccination; Vaccine hesitancy; Mistrust; Communication; Motivation interviewing; ASSOCIATION; COVERAGE; SAFETY; CHALLENGES; STRATEGIES; INFLUENZA; MOVEMENT; REFUSAL; TRENDS; IMPACT;
D O I
10.1016/j.rmr.2018.10.620
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction. - We are at a "post-trust" period, characterised by vaccine hesitancy which is being widely diffused by the media and social networks. The consequences of this include: measles, whooping cough epidemics, vaccine coverage decreasing for the youngest, and remaining at low levels in adults. Mandatory vaccination has been extended for children less than two years in France, with the objective to increase vaccination rates during this period. State of the art. - The medical literature on this topic is increasing, mainly regarding descriptions of reasons for vaccine hesitancy. These include doubt about vaccine efficacy, safety, and real need as well as with regard to social aspects, cultural, religious beliefs. The literature that explores the best way to address vaccine hesitancy is still scarce. Healthcare workers are a key in promoting vaccine acceptance. There is a need to address the issue of vaccine hesitancy in a multicompartmental way. Health authorities must communicate in a clear and concise style that is trust-based and science-informed, being transparent both on vaccine benefits and on issues around vaccine safety. For caregivers, motivational interviewing can help patients change behaviour. Conclusion. - Anti-vaccine ideas were born with vaccines; they are abundantly spread through the Internet and social networks and can give a false impression of their basis in reality. It is time for positive action not merely a defensive approach. (C) 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:962 / 970
页数:9
相关论文
共 45 条
  • [1] [Anonymous], 2014, WHO SAGE STRAT ADR V
  • [2] [Anonymous], 2016, WEEKLY REPORT INFECT, V11
  • [3] Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years
    Asturias, Edwin J.
    Wharton, Melinda
    Pless, Robert
    MacDonald, Noni E.
    Chen, Robert T.
    Andrews, Nicholas
    Salisbury, David
    Dodoo, Alexander N.
    Hartigan-Go, Kenneth
    Zuber, Patrick L. F.
    [J]. VACCINE, 2016, 34 (29) : 3342 - 3349
  • [4] Barnighausen T, 2014, PNAS, V34, P12313
  • [5] Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
    Bonten, M. J. M.
    Huijts, S. M.
    Bolkenbaas, M.
    Webber, C.
    Patterson, S.
    Gault, S.
    van Werkhoven, C. H.
    van Deursen, A. M. M.
    Sanders, E. A. M.
    Verheij, T. J. M.
    Patton, M.
    McDonough, A.
    Moradoghli-Haftvani, A.
    Smith, H.
    Mellelieu, T.
    Pride, M. W.
    Crowther, G.
    Schmoele-Thoma, B.
    Scott, D. A.
    Jansen, K. U.
    Lobatto, R.
    Oosterman, B.
    Visser, N.
    Caspers, E.
    Smorenburg, A.
    Emini, E. A.
    Gruber, W. C.
    Grobbee, D. E.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (12) : 1114 - 1125
  • [6] Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? A Review of the New EU Legislation on Pharmacovigilance
    Borg, John-Joseph
    Aislaitner, George
    Pirozynski, Michal
    Mifsud, Stephen
    [J]. DRUG SAFETY, 2011, 34 (03) : 187 - 197
  • [7] Bracken D, 2017, INT J CHRONIC OBSTR, V12, P2475
  • [8] Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
    Chen, Jieling
    O'Brien, Megan A.
    Yang, H. Keri
    Grabenstein, John D.
    Dasbach, Erik J.
    [J]. ADVANCES IN THERAPY, 2014, 31 (04) : 392 - 409
  • [9] Council of The European Union, COUNC CONCL VACC EFF
  • [10] Vaccine safety evaluation: Practical aspects in assessing benefits and risks
    Di Pasquale, Alberta
    Bonanni, Paolo
    Garcon, Nathalie
    Stanberry, Lawrence R.
    El-Hodhod, Mostafa
    Da Silva, Fernanda Tavares
    [J]. VACCINE, 2016, 34 (52) : 6672 - 6680